Differentiating pulmonary hypertension associated with protein kinase inhibitors
Abstract Protein kinase inhibitors (PKIs) have been implicated in pulmonary vascular toxicities including risk factors for at least three of the five World Health Organization groups of pulmonary hypertension (PH). These toxicities include direct drug‐induced pulmonary arterial hypertension, an incr...
Main Authors: | Joshua A. Jacobs, Eiman Jahangir, John J. Ryan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-04-01
|
Series: | Pulmonary Circulation |
Subjects: | |
Online Access: | https://doi.org/10.1002/pul2.12075 |
Similar Items
-
Dasatinib-Induced Pulmonary Arterial Hypertension: A Case Report
by: Liu R, et al.
Published: (2021-08-01) -
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
by: Rasha Kaddoura, et al.
Published: (2023-05-01) -
Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension
by: Csilla Fazakas, et al.
Published: (2018-05-01) -
Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices
by: Annette D. Rieg, et al.
Published: (2019-06-01) -
Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
by: John J. Ryan, MD
Published: (2016-12-01)